Oregon Health & Science University researchers reported that combining venetoclax, a BCL2 inhibitor, with palbociclib, a CDK4/6 inhibitor used in breast cancer, produced stronger and more durable anti‑leukemia activity than venetoclax alone in patient samples and mouse models. The team screened 25 drug combinations and prioritized venetoclax+palbociclib for its ability to co‑target cell‑cycle and protein‑synthesis pathways and to mitigate known resistance mechanisms. The paper in Cell Reports Medicine positions CDK4/6 inhibition as a strategy to overcome venetoclax resistance and supports clinical testing of the combination in AML.